Table 1.
Baseline characteristic of 576 patients with locoregionally advanced NPC.
| Characteristic | NAC + CCRT | NAC + IMRT | P |
|---|---|---|---|
| Sex | |||
| Male | 190 | 177 | 0.260 |
| Female | 98 | 111 | |
| Age (years) | |||
| Range | 16–77 | 13–80 | |
| Median | 49 | 50 | |
| <60 | 233 | 218 | 0.129 |
| ≥60 | 55 | 70 | |
| WHO pathology | 0.842 | ||
| Type I | 2 | 3 | |
| Type II | 15 | 13 | |
| Type III | 271 | 272 | |
| T stage* | 0.944 | ||
| T1 | 17 | 17 | |
| T2 | 54 | 58 | |
| T3 | 136 | 129 | |
| T4 | 81 | 84 | |
| N stage* | 0.360 | ||
| N0 | 17 | 20 | |
| N1 | 57 | 70 | |
| N2 | 175 | 154 | |
| N3 | 39 | 44 | |
| Clinical stage* | 0.785 | ||
| III | 177 | 169 | |
| IVA | 71 | 75 | |
| IVB | 40 | 44 | |
| AC | |||
| No | 107 | 120 | 0.268 |
| Yes | 181 | 168 | |
| NAC regimens | 0.343 | ||
| TPF | 56 | 52 | |
| TP | 36 | 49 | |
| GP | 9 | 13 | |
| FP | 187 | 174 | |
| Cycle of NAC | |||
| <2 | 157 | 143 | 0.243 |
| ≥2 | 131 | 145 | |
WHO: World Health Organization. AC: adjuvant chemotherapy; NAC: neoadjuvant chemotherapy; TPF docetaxel/cisplatin/fluorouracil; TP docetaxel/cisplatin, GP gemcitabine/cisplatin; PF cisplatin/fluorouracil.
*The 7th AJCC/UICC staging system.